Analysts Offer Insights on Healthcare Companies: Urogen Pharma Ltd (URGN) and PTC Therapeutics (PTCT)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Urogen Pharma Ltd (URGN) and PTC Therapeutics (PTCT).

Urogen Pharma Ltd (URGN)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd. The company’s shares opened today at $38.48, close to its 52-week low of $36.95.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.9% and a 42.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma Ltd with a $70.33 average price target, implying an 82.8% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $70 price target.

See today’s analyst top recommended stocks >>

PTC Therapeutics (PTCT)

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Hold rating on PTC Therapeutics. The company’s shares opened today at $33.03.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 28.2% and a 52.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on PTC Therapeutics is a Strong Buy with an average price target of $50.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts